期刊文献+

阴沟肠杆菌感染的临床分布及耐药性变迁 被引量:4

Analysis of Clinical Distribution and Drug Resistance of Infection due to Enterobacter cloacae
下载PDF
导出
摘要 目的:分析阴沟肠杆菌感染的临床分布及耐药性变迁,为临床合理用药提供指导。方法:采用临床微生物指南中的常规方法对医院各类标本进行分离培养,对医院近3年阴沟肠杆菌感染的临床分布及耐药性变迁情况进行总结分析。结果:2009年12月-2011年12月,从临床标本中共分离出165株阴沟肠杆菌,菌株的主要来源为痰液、尿液和其他分泌物,分别占50.3%、32.7%和27%;临床药物敏感试验结果显示,阴沟肠杆菌对头孢菌素类、青霉素类、氯霉素和氨基糖苷类的抗菌药物呈现较高的耐药率,对亚胺培南、头孢吡肟比较敏感,而头孢西丁、氨苄西林及头孢唑林对阴沟肠杆菌无效。结论:阴沟肠杆菌主要导致呼吸道和尿路感染,是一种对多种抗菌素耐药的高耐药性细菌,临床医生应结合临床药敏结果合理地选用抗菌药物,以减少耐药菌株的产生和蔓延。 Objective: To investigate the clinical distribution and antimicrobial resistance of infections caused by Etrterobacter cloacae in our hospital for guiding the clinical application of antibiotics reasonably. Methods: Retrospective analysis of the drug resistance situation and specimen distribution were made to the E.cloacae isolated from our hospital in the recent 3 years. Results: Totally 165 strains of E.cloacae were isolated between Dec., 2009 and Dec., 2011, the percentages of these strains isolated from sputum, urine and the others were 50.3%, 32.7% and 27% respectively. Conclusion: E.cloacae mainly causes infections of respiratory tract and urinary tract in clinic. E.cloacae is multidrug resistant and severely resistant to the third generation eepholosporins. It is suggested that antibiotics be used reasonably under the guidance of antibiotic susceptibility testing.
作者 杨至宜 胡塔
出处 《生物技术通讯》 CAS 2014年第5期711-713,共3页 Letters in Biotechnology
关键词 阴沟肠杆菌 耐药性 抗菌药物 Β-内酰胺酶 AMPC酶 Enterobacter cloacae drug resistance antibacterial β-lactamase AmpC
  • 相关文献

参考文献6

二级参考文献37

共引文献50

同被引文献65

  • 1裴晓燕,刘秀梅.阪崎肠杆菌的生物学性状与健康危害[J].中国食品卫生杂志,2004,16(6):550-555. 被引量:80
  • 2Martfnez-Martinez L,Pascual A,Jacoby GA.Quinolone res- istance from a transferable plasmid [J].Lancet, 1998,351 (9105 ) : 797-799.
  • 3Wang M,Tran JH, Jacopy GA, et al.Plasmid-mediated qui- nolone resistance in clinical of Escherichia coli from shanghai,China[J].Antimicrob Agent Chemother,2003,47 (7) :2242-2248.
  • 4Mammeri H,De Loo MV,Poirel L,et al.Emergence of plas- mid-mediated quinolone resistance in Escherichia coli inEurope[J].Antimicrob Agents Chemother, 2005,49( 1 ) : 71- 76.
  • 5Chanal C.National Committee for Clinical Laboratory Stan- dards.Performance standards for antimierobial susceptibility [S].2004, M 100-S 14.
  • 6Mezzatesta ML, Gona F, Stefani S. Enterobacter cloacae complex: clinical impact and emerging antibiotic resistance [ J ]. Future Mi- crobiol, 2012,7(7) :887-902.
  • 7Zheng J, Cui S, Meng J. Effect of transcriptional activators RamA and SoxS on expression of multidrug efflux pumps AcrAB and AcrEF in fluoroquinolone- resistant Salmonella Typhimurium[ J]. J Antimicrob Chemother, 2009,63 ( 1 ) :95-102.
  • 8Keeney D, Ruzin A, Bradford PA. RamA, a transcriptional regu- lator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae [ J ]. Micreb Drug Resist, 2007,13 ( 1 ) : 1-6.
  • 9Bratu S, Landman D, George A, et al. Correlation of the expres- sion of acrB and the regulatory genes marA, soxS and 'ramA with an- timicrebial resistance in clinical isolates of Klebsiella pneumoniae endemic to New York City[J]. J Antimicmb Chemother, 2009,64 (2) :278-283.
  • 10Perez A, Canle D, Latasa C, et al. Cloning, nucleotide sequen- cing, and analysis of the acrAB-TolC efilux pump of Enterobacfer cloacae and determination of its involvement in antibiotic resistance in a clinical isolate[ J]. Antimicrob Agents Chemother, 2007,51 (9) :3247-3253.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部